Meritage Portfolio Management Fate Therapeutics Inc Transaction History

Meritage Portfolio Management

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 26, 2021	SELL	$59.27 - $95.73 $147,760 - $238,654	-2,493 Closed	0 $0
Q2 2021 Jul 26, 2021	BUY	$67.25 - $92.52 $167,654 - $230,652	2,493 New	2,493 $216,000
Q1 2021 Apr 27, 2021	SELL	$72.16 - $117.4 $233,654 - $380,141	-3,238 Closed	0 $0
Q4 2020 Feb 03, 2021	BUY	$38.09 - $100.95 $123,335 - $326,876	3,238 New	3,238 $294,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Meritage Portfolio Management, based on Form 13F filings with the SEC.

Stay updated on Meritage Portfolio Management with notifications on news.